Abstract: The present invention provides pharmaceutically acceptable salts of compounds of Formula I that are potent EP4 receptor antagonists and can be used for treating cancer or inflammatory diseases alone or in combination with antibody therapy, radiation therapy, anti-metabolite chemotherapy to a subject in need thereof.
Type:
Application
Filed:
March 4, 2019
Publication date:
March 18, 2021
Applicants:
SHENZHEN IONOVA LIFE SCIENCE CO., LTD., FOSHAN IONOVA BIOTHERAPEUTICS CO., INC.
Abstract: The use of EP4 receptor antagonist compounds represented by Formula (I) (or pharmaceutically acceptable salts thereof) as defined herein is provided for treating cancer or inflammatory disease by administering such an EP4 antagonist alone or in combination with an antibody therapy, radiation therapy, anti-metabolite chemotherapy to a subject in need thereof.
Type:
Application
Filed:
February 2, 2019
Publication date:
November 12, 2020
Applicants:
Shenzhen Ionova Life Science Co., Ltd., Foshan Ionova Biotherapeutics Co., Inc.